Referencias bibliográficas

1. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008;134(6):1655–69
2. Anthony PP, Ishak KG, Nayak NC, Poulsen HE, Scheuer PJ, Sobin LH. The morphology of cirrhosis: definition, nomenclature, and classification. Bull World Health Organ 1977;55(4):521–40
3. Wanless IR. Vascular disorders. In: Burt AD, Portmann BC, Ferrell LD eds. MacSween's Pathology of the Liver. 5th ed. Philadelphia: Churchill Livingstone; 2007:613–48
4. Crawford JM. Evidence-based interpretation of liver biopsies. Lab Invest 2006;86(4):326–34
5. Garcia-Tsao G, Friedman S, Iredale J, Pinzani M. Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. Hepatology 2010;51(4):1445–9
6. Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 2004;99(6):1160–74
7. Bedossa P, Poynard T; The METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996;24(2):289–93
8. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003;39(2):239–44
9. Goldin RD, Goldin JG, Burt AD. Intra-observer and inter-observer variation in the histopathological assessment of chronic viral hepatitis. J Hepatol 1996;25(5):649–54
10. Scheuer PJ. Liver biopsy size matters in chronic hepatitis: bigger is better. Hepatology 2003;38(6):1356–8
11. Schiano TD, Azeem S, Bodian CA. Importance of specimen size in accurate needle liver biopsy evaluation of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2005;3(9):930–5
12. Schlichting P, Hølund B, Poulsen H. Liver biopsy in chronic aggressive hepatitis. Diagnostic reproducibility in relation to size of specimen. Scand J Gastroenterol 1983;18(1):27–32
13. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001;344(7):495–500
14. Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38(6): 1449–57
15. Colombo M, Del Ninno E, de Franchis R. Ultrasound-assisted percutaneous liver biopsy: superiority of the Tru-Cut over the Menghini needle for diagnosis of cirrhosis. Gastroenterology 1988;95(2):487–9
16. Vargas-Tank L, Martínez V, Jirón MI, Soto JR, Armas-Merino R. Tru-cut and Menghini needles: different yield in the histological diagnosis of liver disease. Liver 1985;5(3): 178–81
17. Poynard T, McHutchison J, Manns M. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122(5):1303–13
18. Dienstag JL, Goldin RD, Heathcote EJ. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003;124(1):105–17
19. Czaja AJ, Carpenter HA. Decreased fibrosis during cortico-steroid therapy of autoimmune hepatitis. J Hepatol 2004; 40(4):646–52
20. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Non-alcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 2004;39(6):1647–54
21. Falize L, Guillygomarc'h A, Perrin M. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology 2006;44(2):472–7
22. Bortolotti F, Guido M, Cadrobbi P. Spontaneous regression of hepatitis B virus-associated cirrhosis developed in childhood. Dig Liver Dis 2005;37(12):964–7
23. Malekzadeh R, Mohamadnejad M, Rakhshani N. Reversibility of cirrhosis in chronic hepatitis B. Clin Gastroenterol Hepatol 2004;2(4):344–7
24. Serpaggi J, Carnot F, Nalpas B. Direct and indirect evidence for the reversibility of cirrhosis. Hum Pathol 2006; 37(12):1519–26
25. Wanless IR, Nakashima E, Sherman M. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med 2000; 124(11):1599–607
26. Knodell RG, Ishak KG, Black WC. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1(5):431–5
27. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991;13(3):372–4
28. Ludwig J. The nomenclature of chronic active hepatitis: an obituary. Gastroenterology 1993;105(1):274–8
29. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19(6):1513–20
30. Hytiroglou P, Thung SN, Gerber MA. Histological classification and quantitation of the severity of chronic hepatitis: keep it simple!. Semin Liver Dis 1995;15(4): 414–21
31. Ishak K, Baptista A, Bianchi L. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22(6):696–9
32. Germani G, Burroughs AK, Dhillon AP. The relationship between liver disease stage and liver fibrosis: a tangled web. Histopathology 2010;57(6):773–84
33. Lagging LM, Westin J, Svensson E. Progression of fibrosis in untreated patients with hepatitis C virus infection. Liver 2002;22(2):136–44
34. Scheuer PJ, Standish RA, Dhillon AP. Scoring of chronic hepatitis. Clin Liver Dis 2002;6(2):335–347; v–vi
35. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94(9):2467–74
36. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44(1):217–31
37. Burroughs AK, Cholongitas E. Non-invasive tests for liver fibrosis: encouraging or discouraging results? J Hepatol 2007; 46(5):751–5
38. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48(5):835–47
39. Standish RA, Cholongitas E, Dhillon A, Burroughs AK, Dhillon AP. An appraisal of the histopathological assessment of liver fibrosis. Gut 2006;55(4):569–78
40. Puchtler H, Meloan SN, Waldrop FS. Are picro-dye reactions for collagens quantitative? Chemical and histochemical considerations. Histochemistry 1988;88(3–6):243–56
41. Rojkind M, Ponce-Noyola P. The extracellular matrix of the liver. Coll Relat Res 1982;2(2):151–75
42. Jimenez W, Parés A, Caballeréa J. Measurement of fibrosis in needle liver biopsies: evaluation of a colorimetric method. Hepatology 1985;5(5):815–8
43. López-De León A, Rojkind M. A simple micromethod for collagen and total protein determination in formalin-fixed paraffin-embedded sections. J Histochem Cytochem 1985; 33(8):737–43
44. James J, Bosch KS, Aronson DC, Houtkooper JM. Sirius red histophotometry and spectrophotometry of sections in the assessment of the collagen content of liver tissue and its application in growing rat liver. Liver 1990;10(1):1–5
45. Calvaruso V, Burroughs AK, Standish R. Computer-assisted image analysis of liver collagen: relationship to Ishak scoring and hepatic venous pressure gradient. Hepatology 2009;49(4):1236–44
46. Duchatelle V, Marcellin P, Giostra E. Changes in liver fibrosis at the end of alpha interferon therapy and 6 to 18 months later in patients with chronic hepatitis C: quantitative assessment by a morphometric method. J Hepatol 1998;29(1):20–8
47. Kage M, Shimamatu K, Nakashima E, Kojiro M, Inoue O, Yano M. Long-term evolution of fibrosis from chronic hepatitis to cirrhosis in patients with hepatitis C: morphometric analysis of repeated biopsies. Hepatology 1997;25(4): 1028–31
48. Nohlgård C, Rubio CA, Kock Y, Hammar H. Liver fibrosis quantified by image analysis in methotrexate-treated patients with psoriasis. J Am Acad Dermatol 1993;28(1):40–5
49. O'Brien MJ, Keating NM, Elderiny S. An assessment of digital image analysis to measure fibrosis in liver biopsy specimens of patients with chronic hepatitis C. Am J Clin Pathol 2000;114(5):712–718
50. Pilette C, Rousselet MC, Bedossa P. Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores. Comparison with serum markers. J Hepatol 1998;28(3):439–46
51. McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010; 59: 1265–9.
52. Raszeja-Wyszomirska J, Szymanik B, Lawniczak M. Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD). BMC Gastroenterol 2010; 10: 67.
53. Fujii H, Enomoto M, Fukushima W, Tamori A, Sakaguchi H, Kawada N. Applicability of BARD score to Japanese patients with NAFLD. Gut. 2009; 58: 1566–7.
54. Loaeza-del-Castillo A, Paz-Pineda F, Oviedo-Cardenas E, Sanchez-Avila F, Vargas-Vorackova F. AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. Ann Hepatol. 2008; 7: 350–7.
55. Fujii H, Enomoto M, Fukushima W. Noninvasive laboratory tests proposed for predicting cirrhosis in patients with chronic hepatitis C are also useful in patients with non-alcoholic steatohepatitis. J Gastroenterol. 2009; 44: 608–14.
56. Cales P, Oberti F, Michalak S. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology. 2005; 42: 1373–81.
57. Neuschwander-Tetri BA, Clark JM, Bass NM. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology. 2010; 52: 913–24.
58. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2010;34:2001-15
59. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009; 7: 1104–12.
60. Tahan V, Canbakan B, Balci H. Serum gamma-glutamyltranspeptidase distinguishes non-alcoholic fatty liver disease at high risk. Hepatogastroenterology. 2008; 55: 1433–8.
61. Qureshi K, Clements RH, Abrams GA. The utility of the 'NAFLD fibrosis score' in morbidly obese subjects with NAFLD. Obes Surg. 2008; 18: 264–70.
62. Wong VW, Wong GL, Chim AM. Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis. Am J Gastroenterol. 2008; 103: 1682–8.
63. Afdhal NH. Diagnosing fibrosis in hepatitis C: is the pendulum swinging from biopsy to blood tests? Hepatology 2003; 37: 972–4.
64. Khan JA, Khan FA, Dilawar M, Ijaz A, Khan NA, Mehmood T. Serum hyaluronic acid as a marker of hepatic fibrosis. J. Coll. Physicians Surg. Pak. 2007; 17: 323–6.
65. Schuppan D, Ruehl M, Somasundaram R, Hahn EG. Matrix as modulator of stellate cell and hepatic fibrogenesis. Semin Liver Dis. 2001; 21: 351–72.
66. Vallet-Pichard A, Mallet V, Nalpas B. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007; 46: 32–6.
67. Parise ER, Oliveira AC, Figueiredo-Mendes C. Noninvasive serum markers in the diagnosis of structural liver damage in chronic hepatitis C virus infection. Liver Int. 2006; 26: 1095–9.
68. Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am. J. Gastroenterol. 1998; 93: 44–8.
69. Poynard T, Aubert A, Bedossa P. A simple biological index for detection of alcoholic liver disease in drinkers. Gastroenterology 1991; 100: 1397–402.
70. Poynard T, Bedossa P. Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. J. Viral Hepat. 1997; 4: 199–208.
71. Forns X, Ampurdanes S, Llovet JM. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986–92.
72. Wai CT, Greenson JK, Fontana RJ. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518–26.